Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat deep vein thrombosis and pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen (enoxaparin sodium) is used in the venous thromboembolism pathway to prevent clot formation.

- Deep vein thrombosis (DVT): prevents clot formation in the deep veins of the legs. - Pulmonary embolism (PE): reduces the risk of emboli traveling to the lungs. - Haemodialysis anticoagulation: maintains circuit patency during haemodialysis sessions.

Enoxaparin sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site bruising or pain. - Minor bleeding such as nosebleeds or gum bleeding. - Hematuria (blood in urine). - Gastrointestinal upset or nausea. - Elevated liver enzymes (transient).

Serious or Rare Side Effects: - Major hemorrhage (internal or intracranial bleeding). - Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as rash, urticaria, or anaphylaxis. - Spinal or epidural hematoma (with neuraxial procedures).

When using Ledraxen, clinicians should consider several safety measures to minimize risk.

- Renal impairment: adjust dose or monitor anti‑Xa levels. - Concomitant anticoagulants: avoid combined use unless medically justified. - Recent surgery or trauma: assess bleeding risk before administration. - Pregnancy and lactation: use only if benefit outweighs potential risk. - History of heparin‑induced thrombocytopenia: contraindicated. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Enoxaparin sodium can interact with other medicines, affecting its anticoagulant effect.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (warfarin, direct oral anticoagulants) – high bleeding risk. - Antiplatelet agents (aspirin, clopidogrel) – increased hemorrhage. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – potentiates bleeding.

Moderate Interactions (Monitor Closely): - Thrombolytic agents (tPA) – enhanced anticoagulation. - Selective serotonin reuptake inhibitors (SSRIs) – may increase bleeding tendency. - ACE inhibitors or ARBs – monitor for additive hypotensive effects.